Pasithea Wins FDA Clearance for Phase 2 Trial of PAS-004 in Cutaneous Neurofibromas

Bitget2026/11/03 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pasithea Therapeutics received FDA clearance to begin a randomized, placebo-controlled Phase 2 trial of PAS-004 for NF1-associated cutaneous neurofibromas.
The condition affects over 95% of people with NF1 and has no FDA-approved systemic therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030700PRIMZONEFULLFEED9868670) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pasithea Wins FDA Clearance for Phase 2 Trial of PAS-004 in Cutaneous Neurofibromas

You may also like

Crypto prices